Transplantation & Cellular Therapy Meetings

Treating chronic graft-versus-host disease with ruxolitinib in both adult and pediatric patients was found to be safe and effective based on data from 2 separate single-center retrospective analyses whose results were presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.

Tania Jain, MBBS, discusses the role of ruxolitinib as treatment of graft-versus-host disease.